Abby White, Author at OneKC

Felixvet Receives FDA Approval for Cefpodoxime Proxetil Tablets

Media Contact:
Paula Flavin
Project/Marketing Manager
D: 816-912-2000
Email: info@felixvet.com

Felixvet Receives FDA Approval for Cefpodoxime Proxetil Tablets

Kansas City, Mo. — October 30, 2025 — Felixvet is dedicated to advancing veterinary care and addressing the needs of veterinarians, pet owners and distributors. To further this commitment, Felixvet is now introducing Cefpodoxime Proxetil tablets, an antimicrobial indicated for the treatment of skin infections in dogs. Felixvet, Inc., a manufacturer based in Ireland of generic pharmaceuticals for companion animals, established its North American headquarters in Kansas City, Missouri, in 2023.

“Felixvet is committed to providing affordable options without sacrificing quality or reliability,” said Vince Palasota, President of North America at Felixvet. “We adhere to rigorous FDA standards, ensuring safety and efficacy in every product.”

Cefpodoxime Proxetil is a broad-spectrum antibiotic, effective against a wide variety of bacteria. It is primarily prescribed for the treatment of skin infections in dogs, such as those caused by Staphylococcus and Streptococcus bacteria. It works by interfering with the production of bacterial cell walls, ultimately killing vulnerable bacteria. Cefpodoxime Proxetil is a third-generation cephalosporin, meaning it has a wider range of efficacy as compared to previous generations.

Cefpodoxime Proxetil is easy to administer, with its single daily dosing. It is available in 100 mg and 200 mg tablets and is intended for oral use in dogs only.

Felixvet established its North American headquarters in Kansas City, Missouri, in 2023. Felixvet currently holds 20 FDA approvals, with multiple additional products in development and launches planned across a broad range of therapeutic categories.

For more information, contact info@felixvet.com.

About Felixvet:

Founded in 2015 by Dr. Shumeet Banerji, Jon Symonds and Neeraj Agrawal, Felix is in the business of developing bioequivalent generic pharmaceutical products for companion animals. The company’s initial focus is to market and distribute these products in North American markets upon approval by the U.S. Food and Drug Administration and Health Canada. Felix aims to be the first truly global generic companion animal pharmaceutical player, focusing on the top 10 veterinary markets of the world. It aims to make bioequivalent generics available at affordable prices from cGMP-compliant manufacturing plants.

The Connector | October 2025

Welcome to The Connector. Fetching the freshest animal health news.

Important Things You Need to Know

Save the Date for The Gathering Networking Event at VMX 2026

The Corridor will be hosting our annual networking reception on Sunday, January 18, from 3:00 to 4:30 p.m. EST in the Regency Rotunda at the Hyatt Regency. Mark your calendars so you don’t miss this event! >> Save the Date

Help Shape the 2026 Animal Health Summit by Sharing Your Ideas for Topics and Speakers

We’re gathering feedback on topics and speakers for the 2026 Animal Health Summit. Your input is key to building sessions that are timely and relevant. Please share your suggestions with the Animal Health Corridor team via the form below. All submissions will be presented to the Corridor Board for final selection. We look forward to your ideas! >> Submit 2026 AHS Programming Ideas

The Final Countdown: Fall Networking is Almost Here

Less than one week! The Corridor’s can’t-miss networking event is almost here. On Oct 21, 4–6 p.m., we’re taking over Vytelle for an evening of great people, big energy and real connections. Grab yours today! >> Register Now

The Non-negotiable Traits of a Leader: Listening, Empathy, and Integrity

In times of uncertainty, teams turn to their leaders for presence, stability, and trust. Turbulent environments test not only the resilience of a business but the character and capability of its leadership. Active listening, cross-functional understanding, and moral clarity form the foundation of a leader teams can believe in during tough times. >> Read Full Blog

Industry News

New HABRI and Chewy Health Study Reveals Tech-Forward Solutions to Strengthen the Human-Animal Bond

Butterfly Network Launches Next-Generation Butterfly iQ3 Vet™ Solution in the United States and Canada

ELIAS Publishes Data on Chemo-Immunotherapy Regimen for Canine Osteosarcoma

Felixvet Receives FDA Approval for Methimazole Coated Tablets

CATalyst Council Releases Feline Market Insights Volume III: Continued Market Outperformance by Cats

ZyVet Animal Health Launches an FDA-Approved Generic Form of Furosemide Tablets

Felixvet Receives FDA Approval for Clindamycin Hydrochloride Tablets

Virbac Reports 1H 2025 Growth Driven by Sales for Specialty and Dental Products

Luna Bioscience’s Recent Research Discoveries Advance Development of Leptospirosis Rapid, Point-of-Care Diagnostic Tests and Recombinant Protein Vaccines

Cliff Miller named 2025 CVM Alumnus of the Year

Dr. Hunter Lang Named 2025 Mentor of the Year Posthumously by Merck Animal Health and the American Association of Bovine Practitioners

Zoetis to Host Webcast and Conference Call on Third Quarter 2025 Financial Results

A Q&A with Satyanarayana Rachagani: Insights on cancer, prevention and progress

Follow the Money: What Recent Funding Tells Us About Pet Industry Innovation

Generic phenylpropanolamine hydrochloride tablets hit the market

International Regulatory Divergence: Exports at Risk

‘Tis the Season for Tightening Wallets: Consumers are Expected to Spend Less

What Pet & Animal Health Leaders Need to Know About Adopting AI Today. Don’t be Left Trailing the Pack!

Save the Date

2026 Animal Health Summit

August 31 – September 1

View Animal Health Corridor Events

Leading Through the Storm: The Power of Listening, Empathy, and Integrity

In times of uncertainty, teams don’t just look to their leaders for answers, they look for presence, stability, and trust. Turbulent environments, whether driven by economic shifts, organizational change, or policy shifts, test not only the resilience of a business but the character and capability of its leadership.

Three traits become non-negotiable in these moments: active listening, cross-functional understanding, and moral clarity. Together, they form the foundation of what teams need most during difficult times: a leader they can believe in.

Active Listening: Being Fully Present

In periods of uncertainty, leaders often feel pressure to move fast and project confidence. But speed without listening can lead to missteps. Now more than ever, teams want to feel heard. They want to know their concerns aren’t just acknowledged, they’re genuinely understood.

Active listening isn’t about waiting to speak. It’s about creating space for others to share openly, without judgment or interruption. It’s about asking follow-up questions, reflecting back what you’ve heard, and making decisions that take people’s input seriously.

The best leaders in turbulent times don’t assume they know how their teams are doing. They ask, they listen, and they act based on what they learn.

Cross-Functional Empathy: Seeing the Bigger Picture

During uncertainty, stress rarely stays contained within one team. Decisions ripple across departments. Solving a problem for one function could inadvertently create challenges for another.

That’s why understanding cross-functional pressure points is critical. Great leaders seek out different perspectives before they act or make decisions. They know how to ask the right questions:

What will this mean for Sales?
How will Administration and Marketing be impacted?
What business functions/units will be impacted by this decision?

Empathetic leadership doesn’t mean avoiding hard choices or decisions. It means making informed ones with full awareness of the downstream effects. When people feel that their unique challenges are seen and respected, collaboration is strengthened, and silos start to disappear.

Being the Moral Compass: Leading with Integrity

Perhaps the most defining trait of a leader in uncertain times is the ability to be a moral compass for the organization. When people aren’t sure what comes next, they pay attention to how decisions are made and what values guide them.

Integrity shows up in small ways: owning mistakes, being transparent about what you know (and what you don’t), and choosing long-term trust over short-term convenience. It also shows up in big ways: standing up for what’s right, even when it’s not easy or popular.

When you lead with moral clarity, you give your team something to anchor to and values become the lens through which decisions are made.

No one can predict the future, but leaders can shape how their teams experience the journey. In the face of the unknown, being an active listener, understanding your organization cross-functionally, and being a consistent moral guide isn’t just good leadership, it’s what keeps organizations grounded, connected, and moving forward.

FWD 2025 | Momentum in Motion

A man cheers the crowd from a stage, joined by a man to the left and a woman in the middle.

What a night! FWD 2025 brought our A/E/C community together in a spectacular space — the perfect backdrop for our biggest celebration yet! We raised a glass to the work that’s shaping our region and making an impact across the globe.

Here’s to the people and ideas powering the future of KC’s design + construction industry!

Luna Bioscience’s Recent Research Discoveries Advance Development of Leptospirosis Rapid, Point-of-Care Diagnostic Tests and Recombinant Protein Vaccines

Researchers from Yale University, in collaboration with Luna Bioscience, Inc., have unveiled a revolutionary diagnostic method that detects leptospiral Virulence-Modifying (VM) proteins in the blood and urine of infected animals, paving the way for early diagnosis, supporting vaccine development and improved understanding of leptospirosis pathogenesis. “This is the first systemic bacterial disease mediated by a toxin (such as tetanus, botulism, diphtheria) that has the potential for rapid antigen/antibody detection by a novel test, with direct implications for similar test development for other veterinary diseases,” says research team leader Dr. Joseph M. Vinetz.

The research has led to the development of monoclonal antibody (mAb)-based capture immunoassay and antibody/antigen detection-based diagnostic tests. These assays directly detect VM proteins and animal antibody responses to these proteins, a recently identified family of leptospiral proteins crucial for disease pathogenesis. The findings are detailed in a paper published in the September 29 online issue of Microbiology Spectrum. https://doi.org/10.1128/spectrum.00018-25

“We have long known that leptospirosis severely impacts multiple organ systems in dogs, leading to conditions like jaundice, acute kidney injury, and pulmonary haemorrhage,” said Dr. Vinetz. Furthermore, in livestock, rapid diagnosis in individuals and herds promises to improve animal health. “Our discovery of these VM proteins as circulating exotoxins gives us a specific target for both diagnostics and potential therapeutic interventions.”

The assay’s success in detecting VM proteins lays the groundwork for developing rapid, inexpensive lateral flow diagnostics suitable at point of care, for both veterinary and human use. Such tools are particularly crucial for resource-limited settings where leptospirosis is most prevalent.

This study was supported by the National Institutes of Health and the America’s Foundation, with significant contributions from Luna Bioscience, Inc.

For further information, please contact:

Carla Devillers, CEO, Luna Bioscience, Inc.

carla@lunabioscience.com +1 (917) 545-7262

Dr. Joseph M. Vinetz
Section of Infectious Diseases, Department of Internal Medicine
Yale University School of Medicine

joseph.vinetz@yale.edu

Yale University Office of Public Affairs & Communications

public.affairs@yale.edu

About Luna Bioscience:

Luna Bioscience, Inc. is a spin-out from Yale University developing solutions for animals and humans to emerging global infectious diseases through novel vaccines, diagnostics and therapeutics. Luna has been supported by a series of peer-reviewed NIH small business grants, a testament to the rigorousness and clinical relevance of its translational science.

About Yale School of Medicine:
Yale School of Medicine, founded in 1810, is a world-renowned center for biomedical research, education, and advanced health care. It ranks among the top medical schools in receipt of research funding from the National Institutes of Health and is a vital part of Yale University.

Source:
Chaurasia R, Jacobs A, Tang J, Dong S, Vinetz JM. Development of Leptospiral Virulence-Modifying Protein Detection Assay: Implications for Pathogenesis and Diagnostic Test Development. Microbiology Spectrum. 2025, embargo release date, 9-29-2025

MORE on LUNA BIOSCIENCE:

Luna Bioscience has established robust data providing a pathway for collaborating with a major development partner for vaccine and rapid diagnostic test development for leptospirosis in dogs and food-producing animals.

Luna’s co-founder and chief executive Carla Devillers told XYZ media outlet that the industry’s top players are interested in the firm’s leptospirosis vaccine and diagnostics, as Luna’s R&D developments are a major improvement on the currently available vaccines that are based on whole killed bacteria. Further, Devillers said that the advent of rapid diagnostics will enable improved case identification, driving further novel leptospirosis vaccine development.

The New Haven, Connecticut-based start-up is working on a universal one-shot leptospirosis vaccine that can provide long-term protection against all Leptospira species and serovars– current vaccines tend to be for 2-5 serovars at a duration of 6-12 months. Luna also believes its recombinant protein approach can produce vaccines with a low cost of goods in comparison to currently marketed products.

The start-up’s advisory board includes animal health industry experts such as Dr. Judy Jarecki-Black (former global head of intellectual property at Merial) and Dr. Fabian Kausche (previously head of global R&D at Boehringer Ingelheim Animal Health as well as chair of PetMedix).

Felixvet Receives FDA Approval for Clindamycin Hydrochloride Tablets

Media Contact:
Paula Flavin
Project/Marketing Manager
D: 816-912-2000
Email: info@felixvet.com

Felixvet Receives FDA Approval for Clindamycin Hydrochloride Tablets

Kansas City, Mo. — September 22, 2025 — Felixvet Inc. is proud to announce a recent FDA approval for Clindamycin Hydrochloride Tablets, an oral antibiotic approved for use in dogs to treat skin infections, abscesses, dental infections and osteomyelitis caused by susceptible bacterial strains.

“With the approval of Clindamycin Hydrochloride Tablets, we’re expanding access to a trusted treatment option that veterinarians rely on for managing common yet potentially serious infections,” said Vince Palasota, President of North America at Felixvet. “This product reflects our ongoing commitment to quality, affordability and clinical relevance.”

Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis and has demonstrated activity against a broad spectrum of aerobic and anaerobic bacteria, including Staphylococcus aureus, Staphylococcus intermedius, Bacteroides fragilis and Clostridium perfringens. It is especially effective for deep-seated infections, such as those in bone or dental tissues.

The tablets are available in 25 mg, 75 mg and 150 mg strengths and are dosed every 12 hours, with duration of treatment varying based on infection type, typically a few days for acute infections and up to 28 days for osteomyelitis.

“Clindamycin is a proven, versatile therapeutic, and we’re proud to add it to our growing portfolio,” added Palasota. “We look forward to continuing to deliver solutions that meet the daily needs of veterinarians and their patients.”

For more information, contact info@felixvet.com.

About Felixvet:

Felixvet Receives FDA Approval for Methimazole Coated Tablets

Media Contact:
Paula Flavin
Project/Marketing Manager
D: 816-912-2000
Email: info@felixvet.com

Felixvet Receives FDA Approval for Methimazole Coated Tablets

Kansas City, MO — September 19, 2025 — Felixvet Inc. has received the first FDA generic approval for Methimazole Coated Tablets, an antithyroid drug indicated for the treatment of hyperthyroidism in cats. With this milestone, Felixvet continues to advance its mission of offering high-quality, affordable medications for companion animals. The company established its North American headquarters in Kansas City, Missouri, in 2023 and aims to serve veterinarians, pet owners and distributors alike.

The U.S. Food and Drug Administration approved Methimazole Coated Tablets (ANADA 200-814) after determining the product is bioequivalent to the pioneer drug, Felimazole (NADA 141-292), originally approved in 2009. The approval followed a rigorous review of the drug’s safety and manufacturing quality.

“Felixvet is committed to meeting the clinical needs of veterinarians while offering affordable, reliable alternatives,” said Vince Palasota, President of North America at Felixvet. “Each of our products is developed to the highest regulatory standards to ensure consistency, quality and therapeutic equivalence.”

Hyperthyroidism is most commonly diagnosed in senior felines and results from an overproduction of thyroid hormones that may cause symptoms such as weight loss, increased thirst and urination, vomiting and hyperactivity. Methimazole Coated Tablets help manage this disease by inhibiting the synthesis of thyroid hormones.

Methimazole Coated Tablets are film-coated, which can aid in administration, and are supplied in 2.5 mg and 5 mg strengths for oral use. They are administered every 12 hours with dosage adjustments made in 2.5 mg increments, based on a cat’s response and veterinary guidance.

“Methimazole is an important therapy for managing feline hyperthyroidism, and we’re proud to add it to our growing portfolio,” added Palasota. “We look forward to continuing to deliver solutions that meet the daily needs of veterinarians and their patients.”

For more information, email info@felixvet.com.

About Felixvet:

Twenty Years of Innovation, and the Animal Health Corridor is Just Getting Started

Twenty years ago, the Animal Health Corridor was just an idea—a bold vision to connect talent, ideas, and opportunity in one of the most vital industries in the world.

Today, it is a global movement.

We’ve helped bring 85 companies to the Kansas City region. We’ve partnered with more than 600 innovators from 30 countries. We’ve added 4,500 new jobs, $405 million in payroll, and over $4 billion in capital investment.

Twenty years of innovation. Twenty years of growth. Twenty years of shaping the future of animal health together.

But we’re not here to focus on the past. We’re here to build the future.

At the 2025 Animal Health Summit, we launched the Animal Health Corridor Workforce Campaign, a rallying cry for the next generation of our industry.

Because here’s the truth: animal health faces a growing talent gap. There’s a new generation full of passion, skill, and purpose who just don’t know we’re looking for them.

It’s time we changed the narrative.

Most people hear “animal health” and picture a veterinarian. And yes, veterinarians are vital. But our industry is so much more.

Animal health needs microbiologists and AI developers. It needs engineers, marketers, coders, and storytellers. It needs data analysts, technicians, and strategists. It needs people from every background who care about impact, purpose, and innovation.

Animal health takes all kinds.

So how do we reach them? How do we spark their curiosity and help them see a future here?

That’s where you come in.

Whether you’re a global enterprise or a startup founder, a scientist or a service provider, you have a role to play. We’ve built a powerful, ready-to-use campaign designed with the industry’s voice in mind, including outreach materials, videos, graphics, messaging templates, classroom-ready content, and more. It’s all waiting for you at ExploreAHCareers.com.

But more than tools, we need your voice.

Start a conversation with your team. Talk to a local school. Reach out to your alma mater. Tell someone, “This industry needs someone exactly like you.”

Because that single moment of encouragement? It could change a life.

And thousands of moments like that? They will transform our industry.

This is our moment to lead with unity, clarity, and heart.

Let’s make animal health impossible to overlook.

So don’t just be inspired. Take action.

Visit ExploreAHCareers.com.
Download the tools.
Share the message.
Start a conversation.

Together, we’re building the future of animal health.

And the best part? We’ve only just begun.

The Connector | September 2025

Welcome to The Connector. Fetching the freshest animal health news.

Important Things You Need to Know

Animal Health Summit stage and big screen

20 Years in the Making. The Future Ahead.

At the 2025 Animal Health Summit, we celebrated two decades of impact in the Corridor and unveiled our new Workforce Recruitment Campaign, a bold initiative designed to attract and grow the next generation of talent. If you missed the energy in the building, don’t miss your chance to help shape the future. Share your ideas for 2026 programming today.

>> 2025 Summit Video

>> Save the Date: Summit ’26

Helping You Build the Future Workforce of Animal Health

We’ve launched our Workforce Recruitment Campaign to support companies and organizations across the industry in finding and engaging the next generation of talent. This effort is designed with you in mind, providing ready-to-use tools, messaging, and shareable resources to make recruitment easier and more impactful.

All materials are available on ExploreAHCareers.com, where you’ll find everything you need to showcase animal health careers and spotlight our industry as a hub of innovation, impact, and opportunity. Access the toolkit today and put it to work for your organization. Need assistance? Email Corridor Vice President, Emily McVey, with your inquiries!

>> Workforce Recruitment Toolkit

The Corridor’s Can’t-Miss Networking Night

October 21 from 4 to 6 p.m. we’re taking over Vytelle for an evening that’s all about good people, good energy, and a darn good time. This isn’t another box to check. It’s the kind of night you’ll want to show up for. Grab your spot and join the party! >> Register Now

20 Years of Progress, One Future to Build: Join the Animal Health Workforce Movement

For twenty years, the Animal Health Corridor has fueled innovation and growth—attracting companies, creating jobs, and investing billions in the Kansas City region. Now, the focus shifts to the future with the launch of the Workforce Campaign, tackling the industry’s biggest challenge: closing the talent gap. From scientists to storytellers, animal health needs every skill set, and with tools at ExploreAHCareers.com, it’s time for all of us to inspire the next generation to join. >> Read Full Blog